SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Jansson Jan Hakan)
 

Sökning: WFRF:(Jansson Jan Hakan) > Uppsala universitet > Levodopa-carbidopa ...

  • Pålhagen, Sven E.Karolinska University Hospital, Sweden,Karolinska Univ Hosp, Dept Neurol, SE-14186 Stockholm, Sweden (författare)

Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinsons disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs

  • Artikel/kapitelEngelska2016

Förlag, utgivningsår, omfång ...

  • ELSEVIER SCI LTD,2016
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:liu-131707
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-131707URI
  • https://doi.org/10.1016/j.parkreldis.2016.06.002DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:134148541URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-300787URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies|AbbVie Inc.
  • Background: Continuous infusion of levodopa-carbidopa intestinal gel (LCIG) can effectively manage motor and non-motor complications in advanced Parkinsons disease (PD). Healthcare costs, quality of life (QoL), effectiveness, and tolerability were assessed in routine care treatment with LCIG. Methods: The seventy-seven patients enrolled in this prospective, open-label, 3-year study in routine medical care were LCIG-naive (N = 37), or had previous LCIG treatment for amp;lt;2 (N = 22), or amp;gt;= 2 (N = 18) years. Healthcare costs were collected monthly. PD symptoms and QoL were assessed with the Unified Parkinsons Disease Rating Scale (UPDRS), 39-item Parkinsons Disease Questionnaire (PDQ-39), and EuroQoL 5-Dimension Visual Analog Scale (EQ-5D VAS); LCIG dose, safety, and tolerability were monitored. Results: Mean monthly costs per patient ( 8226 5952) were similar across cohorts, remained steady during 3-year follow-up, and increased with PD severity and QoL impairment. In LCIG-naive patients, significant improvements compared to baseline were observed on the UPDRS total score and PDQ-39 summary index score through 18 months (n = 24; UPDRS, p = 0.033; PDQ-39, p = 0.049). Symptom control was maintained during 3-year follow-up in LCIG-experienced cohorts. Small changes in mean daily LCIG dose were observed. Adverse events were common and generally related to the device, procedure, levodopa, or laboratory evaluations. Conclusions: Costs in LCIG-treated patients were stable over 3 years. LCIG treatment led to significant improvements in motor function and QoL over 18 months in LCIG-naive patients and no worsening was observed in LCIG-experienced patients over 3 years despite natural PD progression over time. The longterm safety was consistent with the established LCIG profile. (C) 2016 AbbVie Inc. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Sydow, OlofKarolinska University Hospital, Sweden,Karolinska Univ Hosp, Dept Neurol, SE-14186 Stockholm, Sweden (författare)
  • Johansson, AndersUppsala universitet,Karolinska Institutet,Neurologi(Swepub:uu)andejoha (författare)
  • Nyholm, DagUppsala universitet,Neurologi(Swepub:uu)danyh856 (författare)
  • Holmberg, BjornSahlgrens University Hospital, Sweden,Sahlgrens Univ Hosp, Dept Clin Neurosci, Gothenburg, Sweden (författare)
  • Widner, HakanSkåne University Hospital, Sweden,Skane Univ Hosp, Dept Neurol, Lund, Sweden (författare)
  • Dizdar Segrell, NilLinköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Neurologiska kliniken i Linköping,Linkoping Univ, Dept Neurol, Linkoping, Sweden; Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden(Swepub:liu)nildi39 (författare)
  • Linder, JanNorrlands University Hospital, Sweden,Norrlands Univ Hosp, Neuroctr, Dept Neurol, Umea, Sweden (författare)
  • Hauge, ToveMolde Hospital HNR, Norway,Molde Hosp HNR, Dept Neurol, Molde, Norway (författare)
  • Jansson, RasmusSundsvall Hospital, Sweden,Sundsvall Hosp, Dept Geriatr Med & Rehabil, Sundsvall, Sweden (författare)
  • Bergmann, LarsAbbVie Inc, N Chicago, IL USA (författare)
  • Kjellander, SusannaAbbVie AB, Solna, Sweden (författare)
  • Marshall, Thomas S.AbbVie Inc, N Chicago, IL USA (författare)
  • Karolinska University Hospital, SwedenKarolinska Univ Hosp, Dept Neurol, SE-14186 Stockholm, Sweden (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Parkinsonism & Related Disorders: ELSEVIER SCI LTD29, s. 17-231353-80201873-5126

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy